Literature DB >> 3361533

Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study.

C J Needs1, M Smith, J Boutagy, S Donovan, D Cosh, M McCredie, P M Brooks.   

Abstract

Methylprednisolone pulse therapy is often used in patients with severe rheumatoid arthritis (RA). To compare clinical and pharmacokinetic variables of methylprednisolone and oral prednisolone in patients with RA, a controlled crossover study was carried out. Pharmacokinetic variables for methylprednisolone were Vd of 69.9 l, t1/2 of 2.96 h, total plasma clearance of 17.5 l/h. Pharmacokinetic variables for prednisolone were Vd of 47.5 l, t1/2 of 3.08 h and total plasma clearance of 11.3 l/h. During the elimination phase, a secondary rise in methylprednisolone concentration occurred which may be related to enterohepatic circulation. Clinical response to both prednisolone and methylprednisolone was short-lived with neither lasting more than 6 weeks.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3361533

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Pulse methylprednisolone therapy in rheumatoid arthritis: unproved therapy, unjustified therapy, or effective adjunctive treatment?

Authors:  M D Smith; M J Ahern; P J Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  1990-04       Impact factor: 19.103

2.  Pulse methylprednisolone therapy in rheumatoid arthritis.

Authors:  M D Smith
Journal:  Ann Rheum Dis       Date:  1989-09       Impact factor: 19.103

3.  Intra-articular steroids: confounder of clinical trials.

Authors:  H G Taylor; P D Fowler; M J David; P T Dawes
Journal:  Clin Rheumatol       Date:  1991-03       Impact factor: 2.980

4.  Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis.

Authors:  T M Hansen; P Kryger; H Elling; D Haar; M Kreutzfeldt; M W Ingeman-Nielsen; A T Olsson; C Pedersen; A Rahbek; N Tvede
Journal:  BMJ       Date:  1990-08-04

Review 5.  Immunosuppressive drugs and corticosteroids in the treatment of rheumatoid arthritis.

Authors:  M Arnold; L Schrieber; P Brooks
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

Review 6.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response.

Authors:  P J Hayball; D G Cosh; M J Ahern; D W Schultz; P J Roberts-Thomson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.

Authors:  E Roilides; K Uhlig; D Venzon; P A Pizzo; T J Walsh
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

Review 9.  Managing early presentation of rheumatoid arthritis. Systematic overview.

Authors:  R Glazier
Journal:  Can Fam Physician       Date:  1996-05       Impact factor: 3.275

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.